Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Serina Therapeutics Inc (SER)

Serina Therapeutics Inc (SER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,563
  • Shares Outstanding, K 10,786
  • Annual Sales, $ 60 K
  • Annual Income, $ -11,140 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.20
  • Price/Sales 200.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +370,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +12.32%
on 02/06/26
4.08 -41.91%
on 01/29/26
+0.29 (+13.94%)
since 01/06/26
3-Month
1.71 +38.59%
on 12/31/25
4.45 -46.72%
on 11/10/25
-1.75 (-42.48%)
since 11/06/25
52-Week
1.71 +38.59%
on 12/31/25
7.92 -70.08%
on 08/26/25
-2.23 (-48.48%)
since 02/06/25

Most Recent Stories

More News
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"  Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026...

SER : 2.37 (-4.05%)
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc.  (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational...

SER : 2.37 (-4.05%)
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc.  (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational...

SER : 2.37 (-4.05%)
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

– Company addresses FDA requests regarding formulation excipient  – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject...

SER : 2.37 (-4.05%)
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational...

SER : 2.37 (-4.05%)
Serina Therapeutics Provides Regulatory Update on SER-252 Program

- FDA requests additional information on a formulation component - HUNTSVILLE, AL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage...

SER : 2.37 (-4.05%)
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug...

SER : 2.37 (-4.05%)
Serina Therapeutics Secures $5M for Parkinson’s Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Serina Therapeutics...

SER : 2.37 (-4.05%)
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease

$5 million tranche received under up to $20 million financing agreement IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06,...

SER : 2.37 (-4.05%)
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway Evaluating complementary funding...

SER : 2.37 (-4.05%)

Business Summary

Serina Therapeutics Inc. is a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases. Serina Therapeutics Inc., formerly known as AgeX Therapeutics Inc., is based in HUNTSVILLE, Ala.

See More

Key Turning Points

3rd Resistance Point 2.88
2nd Resistance Point 2.68
1st Resistance Point 2.52
Last Price 2.37
1st Support Level 2.16
2nd Support Level 1.96
3rd Support Level 1.80

See More

52-Week High 7.92
Fibonacci 61.8% 5.55
Fibonacci 50% 4.82
Fibonacci 38.2% 4.08
Last Price 2.37
52-Week Low 1.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar